The CDK-inhibitor p27Kip1 is a key regulator of the G1-to-S-phase progression [60] and is known to be inhibited by c-Myc [61], which is also known to regulate the expression of metabolic genes associated with metabolic reprogramming in cancer cells [62]. Here, MYC is linked to cancer.